Merck: starts Phase III trial of Covid-19 drug
(CercleFinance.com) - Merck announced on Thursday the start of a Phase 3 study to assess the efficacy of its Lavegrio (molnupiravir) tablet in the treatment of Covid-19 in patients at risk of disease progression.
The double-blind, placebo-controlled study is currently enrolling adults aged 18 years or older who have been symptomatic for less than four days and are not yet hospitalized.
Merck points out that Lavegrio has been approved in a number of countries, including Japan and Australia, and can be prescribed as an emergency treatment in the United States for certain adults with Covid.
According to the pharmaceutical company, its drug has already been administered to over 8.3 million patients worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The double-blind, placebo-controlled study is currently enrolling adults aged 18 years or older who have been symptomatic for less than four days and are not yet hospitalized.
Merck points out that Lavegrio has been approved in a number of countries, including Japan and Australia, and can be prescribed as an emergency treatment in the United States for certain adults with Covid.
According to the pharmaceutical company, its drug has already been administered to over 8.3 million patients worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.